 | |
| Clinical data | |
|---|---|
| Trade names | With fluticasone: Breo Ellipta, Relvar Ellipta With umeclidinium: Anoro Ellipta With both: Trelegy Ellipta |
| AHFS/Drugs.com | Monograph |
| License data | |
| Pregnancy category |
|
| Routes of administration | By inhalation |
| Legal status | |
| Legal status | |
| Identifiers | |
| |
| Chemical and physical data | |
| Formula | C24H33Cl2NO5 |
| Molar mass | 486.43 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Vilanterol is a medication primarily used to treat chronic obstructive pulmonary disease (COPD).[2] It may also be used to prevent worsening in asthma.[1] It is inhaled in combination with other medications.[1]
Common side effects include nose and throat irritation, thrush, and chest pain.[2] Other side effects may include anaphylaxis and bronchospasm.[2] It is a long-acting β2 adrenoreceptor agonist (LABA).[2]
Vilanterol in combination with fluticasone was approved for medical use in the United States in 2013.[3] It is also avaliable as umeclidinium/vilanterol and fluticasone/umeclidinium/vilanterol.[2][1] In the United Kingdom a month of medication costs the NHS about £20 to £45 as of 2021.[1] In the United States this amount costs about 190 USD.[4]
References edit
- ^ a b c d e BNF (80 ed.). BMJ Group and the Pharmaceutical Press. September 2020 – March 2021. p. 279. ISBN 978-0-85711-369-6.
{{cite book}}: CS1 maint: date format (link) - ^ a b c d e f g "Vilanterol Monograph for Professionals". Drugs.com. Archived from the original on 17 January 2021. Retrieved 15 September 2021.
- ^ "FDA approves Breo Ellipta to treat chronic obstructive pulmonary disease". web.archive.org. 18 January 2017. Archived from the original on 18 January 2017. Retrieved 15 September 2021.
{{cite web}}: CS1 maint: bot: original URL status unknown (link) - ^ "Breo Ellipta Prices, Coupons & Savings Tips - GoodRx". GoodRx. Archived from the original on 25 April 2020. Retrieved 15 September 2021.